ESH Webcast & Video Podcast of the ESH-iCMLf 13th International Conference CHRONIC MYELOID LEUKEMIA - Biology and Therapy powered by - MULTIWEBCAST

1 presentation / course

CML . Reminiscences and dreams
by John Goldman

2011-09-22 24 minutes

Session 1: LEUKEMIA HSC BIOLOGY AND NOVEL THERAPEUTIC APPROACHES FOR CML ERADICATION

5 presentations / courses

Reconstructing CML stem cell niche using patient-derived induced pluripotent ... by Ali Turhan to be announced! (Waiting for speaker approval)	Finding the soft spot: targeting CML stem cells by Mike Deininger 2011-09-22 18 minutes
A novel AHI-1-BCR-ABL-JAK2 interaction complex mediates cellular resistance t... by MIN CHEN 2011-09-22 13 minutes	Altered microenvironmental niche regulation of leukemia and normal stem cells... by Ravi Bhatia to be announced! (Waiting for speaker approval)
BCL6 is required for the initiation and maintenance of CML by Christian Hurtz 2011-09-22 10 minutes

Session 2: GENETICS, BIOLOGY AND POSSIBLE THERAPIES FOR CML IN BLASTIC TRANSFORMATION

5 presentations / courses

Elucidation of novel epigenetic mechanisms driving human LSC generation by Anil Sadarangani to be announced! (Waiting for speaker approval)	Awakening dormant human blast crisis leukemia stem cells with a therapeutic s... by Alice Y. Shih to be announced! (Waiting for speaker approval)
Keynote Lecture: Blastic transformation: top ten hits and potential therapies by Danilo Perrotti to be announced! (Waiting for speaker approval)	The pan-BCL2 family inhibitor, sabutoclax, selectively targets bone marrow ni... by Daniel J. Goff to be announced! (Waiting for speaker approval)
Targeting of a novel MNK-eIF4E-b-catenin axis in blast crisis CML inhibits le... by Sharon Lim 2011-09-22 11 minutes

Session 3: ALTERNATIVE AVENUES TO TARGET CML STEM/PROGENITOR CELLS

6 presentations / courses

Targeting inhibitory phosphatase signaling in CML by Markus Müschen to be announced! (Waiting for speaker approval)	Evaluation of the efficacy and mechanism of action of the JAK2 inhibitor INCB... by Paolo Gallipoli 2011-09-22 8 minutes
Characterization of three novel and non-immunosuppressive FTY720 derivatives ... by Paolo Neviani to be announced! (Waiting for speaker approval)	Keynote Lecture: Pharmacological targeting of leukemic stem cells in CML: new... by Rick van Etten to be announced! (Waiting for speaker approval)
Inhibition of the PI3K/Akt/mTOR pathway induces cell death and protective aut... by Gudmundur Vignir Helgason 2011-09-22 12 minutes	General discussion by Panel Discussion to be announced!

Session 4: GENOMIC INSTABILITY AND GENETICS OF

6 presentations / courses

Genomic instability originates from leukimia stem cells in a mouse model of C... by Elisabeth Bolton to be announced! (Waiting for speaker approval)	DNA repair gene RAD52 is essential for BCR-ABL1-mediated transformation of he... by Kimberly Cramer to be announced! (Waiting for speaker approval)
Keynote Lecture: Enhanced oxidative DNA damage in CML stem cells: should we i... by Tomasz Skorski to be announced!	General Discussion by Panel Discussion 2011-09-22 2 minutes
A novel BIM polymorphism mediates resistance to BCR-ABL inhibitors in CML by King Pan Ng 2011-09-22 10 minutes	Identification of novel kinase-activating rearrangements in BCR-ABL 1-like AL... by Kathryn Roberts 2011-09-22 11 minutes

Session 5: ABL TYROSINE KINASE INHIBITORS (1): BIOLOGY

5 presentations / courses

Intrinsic and extrinsic survival signals converge upon activation of STAT3 an... by Anna Eiring to be announced! (Waiting for speaker approval)	Targeting the BCR-ABL/SH2 interface by Giulio Superti-Furga to be announced! (Waiting for speaker approval)
Irreversibel apoptosis commitment of CML cells following acute exposure to ty... by Thomas O\'Hare 2011-09-22 15 minutes	Sensitivity to imatinib in BCR-ABL1-positive CML cells is regulated by remain... by Yashodhara Dasgupta 2011-09-22 8 minutes
Keynote lecture: 10 years of imatinib resistance- heaps of mutations and a do... by Oliver Hantschet 2011-09-22 22 minutes

Session 6: IMMUNOLOGICAL TARGETS AND MONITORING AT LOW LEUKEMIA LEVEL

5 presentations / courses

Keynote Lecture: Vaccine and antibody therapy for CML by David Scheinberg to be announced! (Waiting for speaker approval)	Man versus machine: a semi-automated platform for BCR-ABL QPCR by Jerry Radich 2011-09-22 14 minutes
Tyrosine kinase inhibitors modulate the B-cell response to vaccination in CML by Katayoun Rezvani to be announced!	IL1-RAP update by Thoas Fioretos to be announced! (Waiting for speaker approval)
Distinct graft-vs-leukimic stem cell of early or delayed donor leukocyte infu... by Yi-Fen Lu 2011-09-22 14 minutes

Session 7: ABL TYROSINE KINASE INHIBITORS (2): BIOLOGY AND RESISTANCE

4 presentations / courses

The BELA trial: 18-month update on safety and clinical activity in patients w... by carlo gambacorti 2011-09-22 10 minutes	RAF1 is a crucial mediator of BCR-ABL driven leukemogenesis by Justus Duyster to be announced! (Waiting for speaker approval)
Multiple non-resistant low-level BCR-ABL1 mutations in CML patients after ima... by Susan Branford 2011-09-22 11 minutes	Updated phase 1 data on ponatinib, a pan-BCR-ABL inhibitor, in CML and other ... by Jorge Cortes 2011-09-22 14 minutes

Brief Oral Communications (biology)

6 presentations / courses

Use of genetic engineering to model disease progression in CML reveals distin... by Ivan Sloma to be announced! (Waiting for speaker approval)	Targeting DNA checkpoint/repair proteins as a strategy for the treatment of CML by Mary Scott to be announced! (Waiting for speaker approval)
Targeting STAT5 in CML: Mechanism-of-action of JAK2 tyrosine kinase inhibitor... by Wolfgang Warsch 2011-09-22 6 minutes	Sirt1 co-operates with TGF-b signal to suppress BCR-ABL1-dependent cell growt... by Hu Ming to be announced!
Rac2 - mitochondrial respiratory chain complex III signaling generates reacti... by Piotr Kopinski 2011-09-22 5 minutes	Regulation of mature versus immature conformation of BCR-ABL by Yoshiro Maru 2011-09-22 4 minutes

Session 8: CML CLINICAL ASPECTS AND NEW TRIALS

6 presentations / courses

Assessment of BCR-ABL1 transcripts at 3 months predicts patient outcome by David Marin to be announced! (Waiting for speaker approval)	The TIDEL II strategy of imatinib dose intensification and nilotinib switch m... by Deborah White to be announced! (Waiting for speaker approval)
Keynote lecture: What questions remain and how can we answer them? by Jane Apperley to be announced! (Waiting for speaker approval)	How do we define the \'best\' front-line therapy for CML and can we afford it? by Stephen O\'Brien 2011-09-22 16 minutes
Optimising frontline therapy in CML: Developing a treatment algorithm based o... by Tim Hughes to be announced! (Waiting for speaker approval)	A Phase 1 study of DCC-2036, an oral novel inhibitor of Abl kinase, in adult ... by Jorge Cortes 2011-09-22 11 minutes

Brief Oral Communications (Clinical)

8 presentations / courses

BCR-ABL compound mutations in CML by Jamshid Khorashad 2011-09-24 7 minutes	Correlation of hOCT1 genetic polymorphisms with the clinical outcome Athina G... by Athina Giannoudis 2011-09-24 5 minutes
Switching to nilotinib vs imatinib dose escalation for patients with suboptim... by David T Yeung 2011-09-24 6 minutes	High BCR-ABLIS expression levels at diagnosis and after 3 and 6 months of tre... by Paolo Vigneri 2011-09-24 5 minutes
The Prognostic significance of Molecular and Cytogenetic response landmarks a... by Benjamin Hanfstein 2011-09-24 5 minutes	Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib r... by Thomas Ernst to be announced! (Waiting for speaker approval)
Loss of major molecular response is the most accurate criteria for restarting... by Philippe Rousselot to be announced! (Waiting for speaker approval)	Residual normal stem cells can be detected in newly diagnosed CML patients by... by Jeroen Janssen 2011-09-24 4 minutes

Session 9: MINI-DEBATES : TOPICAL BIOLOGICAL QUESTIONS N°1

3 presentations / courses

There is a definite need to target stem cells: yes by Mhairi Copland to be announced!	There is a definite need to target stem cells: no by Giovanni Martinelli 2011-09-22 8 minutes
Debate by Panel Discussion to be announced!

Session 9: MINI-DEBATES : TOPICAL BIOLOGICAL QUESTIONS N°2

3 presentations / courses

Genomic instability can be manipulated to induce LSC to self-destruct: yes by Tomasz Skorski to be announced! (Waiting for speaker approval)	Genomic instability can be manipulated to induce LSC to self-destruct: no by Martin Sattler to be announced! (Waiting for speaker approval)
Debate by Panel Discussion to be announced!

Session 9: MINI-DEBATES : TOPICAL BIOLOGICAL QUESTIONS N°3

3 presentations / courses

JAK-2 is clearly an important therapeutic target in CML: yes by MIN CHEN 2011-09-22 9 minutes	JAK-2 is clearly an important therapeutic target in CML: no by Wolfgang Warsch 2011-09-22 9 minutes
Debate by Panel Discussion 2011-09-22 2 minutes

Session 10: MINI-DEBATE: TOPICAL CLINICAL QUESTIONS

9 presentations / courses

All CML patients should start treatment with 2G-TKI: yes by Giovanni Martinelli to be announced! (Waiting for speaker approval)	All CML patients should start treatment with 2G-TKI: no by Charles Schiffer 2011-09-25 17 minutes
Debate by Panel Discussion to be announced!	Maintenance of a stable CCyR is an adequate therapeutic target: yes by Michele Baccarani 2011-09-25 11 minutes
Maintenance of a stable CCyR is an adequate therapeutic target: no by Philippe Rousselot 2011-09-25 6 minutes	Debate by Panel Discussion 2011-09-25 2 minutes
Stopping TKI can now be recommended in selected patients: yes by François-Xavier Mahon 2011-09-25 11 minutes	Stopping TKI can now be recommended in selected partients: no by Giuseppe Saglio 2011-09-25 13 minutes
Debate by Panel Discussion to be announced!

Search’n Build™